![]() RenovoRx RenovoRx is a clinical-stage biopharmaceutical company focused on developing therapies for the local treatment of solid tumors. | SynCore Biotechnology SynCoreBio (杏國新藥股份有限公司) is a biopharmaceutical company engaged in the research and development of drugs with a focus on oncology, ophthalmology, dermatology, and infectious diseases. | ![]() NovoCure NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors. | ![]() TriSalus Life Sciences TriSalus Life Sciences (formerly MedTech Acquisition and Surefire Medical) is a company that develops a transformative platform for treating liver and pancreatic tumors. | ![]() Bausch Health Bausch Health is a company that develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products. | ||
Founding Date | Founding Date 2012 | Founding Date 2008 | Founding Date 2000 | Founding Date 2009 | Founding Date 1959 | Founding Date 1988 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||
Locations | Locations Los Altos, US HQ | Locations TW HQ | Locations Westminster, US HQ Bannockburn, US Cranston, US | Locations Laval, CA HQ Buenos Aires, AR Wien, AT Sarajevo, BA Indaiatuba, BR Porto Alegre, BR Sao Paulo, BR see more | Locations Latham, US HQ Oakville, CA Hong Kong, HK Rehovot, IL Amsterdam, NL Glens Falls, US Marlborough, US see more | |
Employees | Employees 7 | Employees 40 | Employees 1,488 | Employees 106 | Employees 20,700 | Employees 8157% increase |
Valuation ($) | Valuation ($) 24.8 m | Valuation ($) N/A | Valuation ($) 1.8 b | Valuation ($) 117.2 m | Valuation ($) 3 b | Valuation ($) 282 m |
Financial | ||||||
Revenue (est.) | Revenue (est.) $1.1m (FY, 2025) | Revenue (est.) NT$23.3m (FY, 2024) | Revenue (est.) $655.4m (FY, 2025) | Revenue (est.) $45.2m (FY, 2025) | Revenue (est.) $10.3b (FY, 2025) | Revenue (est.) $292.5m (FY, 2025) |
Cost of goods | Cost of goods $327k (FY, 2025) | Cost of goods NT$10.5m (FY, 2024) | Cost of goods $166.9m (FY, 2025) | Cost of goods $7m (FY, 2025) | Cost of goods $1.7b (FY, 2025) | Cost of goods $134.8m (FY, 2025) |
Gross profit | Gross profit $796k (FY, 2025) | Gross profit NT$12.9m (FY, 2024) | Gross profit $488.5m (FY, 2025) | Gross profit $38.2m (FY, 2025) | Gross profit $8.5b (FY, 2025) | Gross profit $157.7m (FY, 2025) |
Net income | Net income ($11.2m) (FY, 2025) | Net income (NT$54.3m) (FY, 2024) | Net income ($136.2m) (FY, 2025) | Net income ($39.2m) (FY, 2025) | Net income $120m (FY, 2025) | Net income ($34m) (FY, 2025) |
Operating ⚠ | ||||||
Manufacturing Facilities | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 37 (FY, 2019) | Manufacturing Facilities 2 (FY, 2023) |
Research and Development Centers | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers 23 (FY, 2019) | Research and Development Centers 2 (FY, 2023) |
Funding | ||||||
Total funding raised | Total funding raised $ 10.2m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 52.2m | Total funding raised N/A | Total funding raised $ 352.1k |
SynCoreBio (杏國新藥股份有限公司) is a biopharmaceutical company engaged in the research and development of drugs with a focus on oncology, ophthalmology, dermatology, and infectious diseases.
View company
NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors.
View company
TriSalus Life Sciences (formerly MedTech Acquisition and Surefire Medical) is a company that develops a transformative platform for treating liver and pancreatic tumors.
View company
Bausch Health is a company that develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products.
View company